Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Multicenter, Therapeutic Used Study to Evaluate the Efficacy and Safety of Pletaal SR Capsule (Cilostazol) in Subjects With Peripheral Arterial Disease Symptom Due to Chronic Occlusive Arterial Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01711333
Recruitment Status : Unknown
Verified October 2012 by Korea Otsuka Pharmaceutical Co., Ltd..
Recruitment status was:  Not yet recruiting
First Posted : October 22, 2012
Last Update Posted : October 24, 2012
Sponsor:
Information provided by (Responsible Party):
Korea Otsuka Pharmaceutical Co., Ltd.

Brief Summary:
This study is to evaluate symptomatic changes and safety before and after the administration of Pletaal® SR Capsules based on Peripheral Artery Questionnaire (PAQ) in subjects with peripheral arterial disease symptom due to chronic occlusive arterial disease (COAD).

Condition or disease Intervention/treatment Phase
Chronic Occlusive Arterial Disease Drug: Pletaal SR capsule Phase 4

Detailed Description:
This is a multinational, single-arm, therapeutic used clinical trial. After screening in subjects with peripheral arterial disease symptom due to chronic occlusive arterial disease, the eligible subjects will be enrolled, followed by the administration of the study drug (two capsules qd of Pletaal SR 100mg Capsules) for 12 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : October 2012
Estimated Primary Completion Date : September 2014
Estimated Study Completion Date : April 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Pletaal SR capsule Drug: Pletaal SR capsule
two capsules once a day of Pletaal SR 100mg Capsules




Primary Outcome Measures :
  1. Summary score based on PAQ (Peripheral artery questionnaire) [ Time Frame: Change from Baseline in PAQ summary score at Week 12 ]

Secondary Outcome Measures :
  1. Score of domain (physical limitation) based on PAQ [ Time Frame: Change from Baseline in PAQ domain (physical limitation) at Week 12 ]
  2. Assessement based on HAQ-DI [ Time Frame: Change from Baseline in HAQ-DI at Week 12 ]
  3. Score of domain(symptom) based on PAQ [ Time Frame: Change from Baseline in PAQ domain(symptom) at Week 12 ]
  4. Score of domain(symptom stability) based on PAQ [ Time Frame: Change from Baseline in PAQ domain(symptom stability) at Week 12 ]
  5. Score ofdomain(social limitation) based on PAQ [ Time Frame: Change from Baseline in PAQ domain (social limitation) at Week 12 ]
  6. Score of domain(treatment satisfaction) based on PAQ [ Time Frame: Change from Baseline in PAQ domain (treatment satisfaction) at Week 12 ]
  7. Score of domain(quality of life) based on PAQ [ Time Frame: Change from Baseline in PAQ domain (quality of life) at Week 12 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or Female outpatients between 40 and 75 years of age,
  2. Patients confirmed to have symptoms of peripheral arterial disease (including intermittent claudication, pain, coldness and fatigue) in the lower extremities,
  3. Patients who have a steady symptom without significant improvement within 12 weeks prior to screening visit and whose PAQ score of the question number 3 is 3 or less at enrollment visit,
  4. Ankle Branchial Index (ABI) ≤0.90 when measuring the pressure in a supine position after resting for 10 minutes,
  5. Patients who are equal to or less than 10% of the difference in PAQ summary scores at between screening and enrollment,
  6. Patients who have been fully explained about this study, voluntarily decided to participate in this study, and provided written informed consent.

Exclusion Criteria:

  1. Patients with ischemic pain at rest or having ischemic ulcer or gangrene,
  2. Patients with Ankle Branchial Index (ABI) ≤ 0.40
  3. Patients who underwent sympathectomy or lower extremity arterial reparative surgery including endovascular procedures within 12 weeks prior to screening visit,
  4. Patients diagnosed of deep vein thrombosis within 12 weeks prior to screening visit, (provided that patients with isolated calf vein thrombosis may be enrolled)
  5. Patients with the following disease:

    • Patients who is on or needs the treatment for Congestive heart failure
    • Myocardial infarction which occurred within 24 weeks prior to screening visit
    • Patients who is on or needs the treatment for unstable angina pectoris,
  6. Patients with hemorrhage (hemophilia, capillary fragility, intracranial hemorrhage, upper gastrointestinal hemorrhage, urinary hemorrhage, hemoptysis, vitreous hemorrhage, etc.) and predisposition to hemorrhage (active peptic ulcer, hemorrhagic stroke within the recent 24 weeks, suspected hemorrhage when administering cilostazol for wound due to surgery within the recent 12 weeks, and proliferative diabetic retinopathy),
  7. PT, aPTT level greater than 1.5 times the upper limit of normal at screening visit,
  8. Uncontrolled hypertension defined as ≥ 160 mmHg of systolic blood pressure or ≥ 100 mmHg of diastolic blood pressure,
  9. Creatinine clearance(Ccr)a ≤ 25mL/min at screening a. Creatinine clearance (Ccr) is calculated by the following modified Cockcroft-Gault formula using the serum creatinine as determined by the site laboratory.

Ccr(mL/min)=[260-age(year)] x Body weight(kg) / 160 x Serum creatinine(mg/dL) (male) Ccr(mL/min)=[236-age(year)] x Body weight(kg) / 180 x Serum creatinine(mg/dL) (female), 10) AST or ALT level greater than 3 times the upper limit of normal at screening, 11) Total bilirubin level greater than 2 times the upper limit of normal at screening, 12) Type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus (HbA1c greater than 9%), 13) Patients determined ineligible to participate in this clinical trial at the discretion of Investigator due to critical diabetic complications (diabetic foot ulcer, foot deformity, etc.), 14) Female patients whose serum pregnancy test at screening or urine pregnancy test at enrollment is positive in case of childbearing potential and breastfeeding women,

  • For female patients, those who have been at their postmenopause at least for one year or longer, who have no potential to be pregnant by surgery or procedure, or who agreed to use acceptable contraceptive methods (intrauterine device [loop or Mirena], double barrier method [diaphragm or condom/femidom + spermicide], vasectomy in spouse, oral contraceptives or non-oral contraceptives) throughout the entire study period,Female patients whose pregnancy test at screening is positive in case of childbearing potential or breastfeeding women 15) History of malignant disease (excluding treated basal cell or squamous cell carcinoma of skin) within 5 years prior to Screening. Resolution of a prior malignancy more than 5 years prior to Screening must be deemed as cured by the investigator, 16) Patients who have history of taking or plan to take the following medications:
  • Cilostazol-containing medications within 12 weeks prior to screening visit,
  • Antiplatelets (such as aspirin and ticlopidine), anticoagulants (such as warfarin), thrombolytics (such as urokinase and alteplase), prostaglandin E1 and its derivatives (such as alprostadil and limaprost), pentoxyfylline, beraprost, sarpogrelate and statin within 4 weeks prior to screening visit. However, aspirin (≤ 100 mg) or statin being taken for more than 4 weeks prior to screening visit may be administered at the same dose.
  • Nitrates, papaverine, isoxsuprine, and NSAIDs within 4 weeks prior to screening visit. However, NSAIDs being taken for more than 4 weeks prior to screening visit may be administered at the same dose, 17) Patients with a history of hypersensitivity to cilostazol, 18) Patients who have received an investigational product or biological agent within 12 weeks prior to screening visit, 19) Patients who plans to enroll in another clinical trial (excluding observational studies) during this study, 20) Patients who needs to stop the Investigational Product because of scheduled operation, extraction of tooth or endoscopy, 21) Patients who are otherwise judged by the investigator to be inappropriate for inclusion in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01711333


Locations
Layout table for location information
Korea, Republic of
KYUNG-HEE UNIVERSITY HOSPITAL at GANGDONG
Seoul, Korea, Republic of
Contact: Kyu Jeung Ahn, PhD    822-440-6125    ahnkj@khnmc.or.kr   
Sponsors and Collaborators
Korea Otsuka Pharmaceutical Co., Ltd.

Layout table for additonal information
Responsible Party: Korea Otsuka Pharmaceutical Co., Ltd.
ClinicalTrials.gov Identifier: NCT01711333    
Other Study ID Numbers: 021-KOA-1102i
First Posted: October 22, 2012    Key Record Dates
Last Update Posted: October 24, 2012
Last Verified: October 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases